Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: Week 28 interim analysis of a Phase 4 study

被引：0
|
作者：
Bhatia, Neal [1 ]
Heim, Jayme [2 ]
Torres, Monique [1 ]
Beute, Paulita [2 ]
Rozzo, Stephen J. [3 ]
Vasquez, J. Gabriel [2 ]
机构：
[1] Therapeut Clin Res, San Diego, CA USA
[2] West Michigan Dermatol, Grandville, MI USA
[3] Sun Pharmaceut Ind Inc, Princeton, NJ USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2022年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [1] Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: Week 28 interim analysis of a phase 4 study
    Bhatia, Neal
    Heim, Jayme
    Torres, Monique
    Beute, Paulita
    Rozzo, Stephen J.
    Vasquez, J. Gabriel
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB199 - AB199
  • [2] A phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis
    Heim, Jayme
    Vasquez, J. Gabriel
    Beute, Paulita
    Torres, Monique
    Rozzo, Stephen J.
    Bhatia, Neal
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB132 - AB132
  • [3] A Phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis
    Heim, Jayme
    Vasquez, J. Gabriel
    Beute, Paulita
    Torres, Monique
    Rozzo, Stephen J.
    Bhatia, Neal
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 6 - 6
  • [4] REAL-WORLD EFFECTIVENESS AND SAFETY IN A PHASE 4 STUDY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Bhatia, N.
    Vasquez, J. G.
    Schenkel, B.
    Rozzo, S. J.
    Heim, J.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S57 - S57
  • [5] Real-world effectiveness of tildrakizumab in a Phase 4 study in patients with moderate-to- severe plaque psoriasis
    Bhatia, Neal
    Vasquez, J. Gabriel
    Schenkel, Brad
    Rozzo, Stephen J.
    Heim, Jayme
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB216 - AB216
  • [6] Safety of tildrakizumab in a Phase 4 real-world study in patients with moderate-to-severe plaque psoriasis
    Vasquez, J. Gabriel
    Bhatia, Neal
    Schenkel, Brad
    Rozzo, Stephen J.
    Heim, Jayme
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB85 - AB85
  • [7] Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis
    Bhatia, Neal
    Heim, Jayme
    Schenkel, Brad
    Vasquez, J. Gabriel
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [8] Patients' quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis
    Heim, Jayme
    Vasquez, J. Gabriel
    Rozzo, Stephen J.
    Schenkel, Brad
    Bhatia, Neal
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB204 - AB204
  • [9] Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis
    Bhatia, Neal
    Vasquez, J. Gabriel
    Schenkel, Brad
    Rozzo, Stephen J.
    Heim, Jayme
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB72 - AB72
  • [10] PSORIASIS-RELATED WORK PRODUCTIVITY IMPROVEMENT FROM A PHASE 4 REAL-WORLD STUDY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
    Bhatia, N.
    Heim, J.
    Schenkel, B.
    Rozzo, S. J.
    Vasquez, J. G.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S346 - S347
12345